Avigen, Inc. (Nasdaq: AVGN) announced that the top-line data from its Phase 2b study of AV650 (tolperisone ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE